About: Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 11 October 2018

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) im Oktober 2018 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'ochobre de 2018 (ast) наукова стаття, опублікована в жовтні 2018 (uk) 2018 թվականի հոկտեմբերի 11-ին հրատարակված գիտական հոդված (hy) scientific article published on 11 October 2018 (en)
publication date	wds:Q57279955-F6ABC852-9B44-4B5B-84AA-70D15304C7AE
publication date	2018-10-11 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57279955-D6FBE9E4-2C38-4834-9841-05425333EC14
language of work or name	English
cites work	wds:Q57279955-137942E8-ADE7-4595-9FF1-D2D2F612C0F1 wds:Q57279955-26CEDA6B-ABE0-400A-A543-32B3F50C4807 wds:Q57279955-3B6999BE-0509-4296-9E8F-2F944B2CA430 wds:Q57279955-47DFDB4A-706B-46DE-B25C-49037D5D239B wds:Q57279955-64D759CF-765B-48F4-98E4-210B95516408 wds:Q57279955-69419546-E7E0-4E89-9C0E-B2BEEB089536 wds:Q57279955-7F1D894A-F5B1-4EA6-B54C-6534F3D98173 wds:Q57279955-82BCE219-D0B4-4DC2-8C03-10DD0DFB02D7 wds:Q57279955-8F7E49DC-DC78-4F9F-BEB2-3A8509FD1A2B wds:Q57279955-96A88299-67A2-4CC6-8185-A2AC8C3DC328 wds:Q57279955-96FE2406-0FD2-4011-BEA2-9929DA9F729F wds:Q57279955-9728A680-25CA-4D9B-A0FD-9F82EF940774 wds:Q57279955-B86C2A64-4084-4B17-B74C-5D47A0A9668F wds:Q57279955-C233F6FB-DD9E-4D17-8E7B-ECF387206420 wds:Q57279955-C78C12AB-1EF3-493B-9B58-406C0B82D6DD wds:Q57279955-C96FE30E-1BB0-4B8E-99FD-D37303CC8D1E wds:Q57279955-D39B801C-F311-476A-B0F7-F6AC6E71F748 wds:Q57279955-D65F34DB-2605-46F1-B50B-14A871F60F1E wds:Q57279955-E538431F-70FE-41C6-A6FD-4636CA2234FC wds:Q57279955-F49488A0-EBFE-498F-85DB-D4F314807ABC wds:Q57279955-F736F0CD-CB62-4F4B-B606-10A2DAF9A5F7
cites work	Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial
author name string	wds:Q57279955-3F164F20-94D9-438B-BB14-E80E9C5545EF wds:Q57279955-71670129-7017-4728-B278-05FDC758ABF9 wds:Q57279955-7A70B40D-AAF7-4F34-A4D2-98CAAEC4CEC8
author name string	Nitin Jain Farhad Ravandi Kathryn Montalbano
rdfs:label	Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage (en) Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage (nl)
skos:prefLabel	Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage (en) Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage (nl)
name	Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage (en) Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage (nl)
author	wds:Q57279955-17C67146-D0CC-410A-AB82-F1E7E6929BC1 wds:Q57279955-222416B1-A1F6-4CDC-8608-B2D80F41B425 wds:Q57279955-4A3B35B8-8AF8-40F4-8C10-02DBF9F22359 wds:Q57279955-58E08271-05DA-4ABD-92DC-57A77666573D wds:Q57279955-72C67187-BD57-4E78-92D0-35BF0B1E1B7C wds:Q57279955-72F7CF33-6654-4E7A-9604-F65B3A14A61C wds:Q57279955-7B5B968D-A819-44D1-BD1B-5DF3ADF835C7 wds:Q57279955-87A91CE6-92F8-4511-9331-50CFE982BB2B wds:Q57279955-8F35F0F1-B086-4165-8A60-FE774A3FA1F2 wds:Q57279955-97D72BC2-14DA-4FD3-90B3-F5E12E0E76CA wds:Q57279955-B6A85B31-0F89-4AE4-BCED-8EFBD74FB035 wds:Q57279955-BC0311D1-2116-49DF-A847-A20B35925F10 wds:Q57279955-C1A97596-A849-46D2-8850-5A38DABBDCAE wds:Q57279955-DC2CE1C7-1BE2-4027-A6C2-8CA5F37F98A4 wds:Q57279955-E1908680-0F34-42D9-A6D6-C65FC6797BC2 wds:Q57279955-E5D0D956-7B10-4DF5-954D-07D0AD95DD09 wds:Q57279955-EB1B5932-AB0D-4A3B-8AD6-2C290215BCFB
author	Marina Konopleva Xuelin Huang Jorge Eduardo Cortes Hagop Kantarjian Guillermo Garcia-Manero Joseph D. Khoury Partow Kebriaei Jeffrey C. Jorgensen Jan A Burger Tapan M Kadia Elias J Jabbour Rebecca S Garris Susan M O'Brien Nicholas J. Short Koji Sasaki Maria R Khouri Jovitta Jacob
title	wds:Q57279955-E3CA3BAB-EDBD-4B9C-929C-5C27AC02395B

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 171 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software